170 related articles for article (PubMed ID: 31443604)
1. L19-IL2 Immunocytokine in Combination with the Anti-Syndecan-1 46F2SIP Antibody Format: A New Targeted Treatment Approach in an Ovarian Carcinoma Model.
Orecchia P; Balza E; Pietra G; Conte R; Bizzarri N; Ferrero S; Mingari MC; Carnemolla B
Cancers (Basel); 2019 Aug; 11(9):. PubMed ID: 31443604
[TBL] [Abstract][Full Text] [Related]
2. Targeting Syndecan-1, a molecule implicated in the process of vasculogenic mimicry, enhances the therapeutic efficacy of the L19-IL2 immunocytokine in human melanoma xenografts.
Orecchia P; Conte R; Balza E; Pietra G; Mingari MC; Carnemolla B
Oncotarget; 2015 Nov; 6(35):37426-42. PubMed ID: 26460958
[TBL] [Abstract][Full Text] [Related]
3. The immunocytokine L19-IL2 eradicates cancer when used in combination with CTLA-4 blockade or with L19-TNF.
Schwager K; Hemmerle T; Aebischer D; Neri D
J Invest Dermatol; 2013 Mar; 133(3):751-758. PubMed ID: 23096716
[TBL] [Abstract][Full Text] [Related]
4. The targeted immunocytokine L19-IL2 efficiently inhibits the growth of orthotopic pancreatic cancer.
Wagner K; Schulz P; Scholz A; Wiedenmann B; Menrad A
Clin Cancer Res; 2008 Aug; 14(15):4951-60. PubMed ID: 18676770
[TBL] [Abstract][Full Text] [Related]
5. A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma.
Eigentler TK; Weide B; de Braud F; Spitaleri G; Romanini A; Pflugfelder A; González-Iglesias R; Tasciotti A; Giovannoni L; Schwager K; Lovato V; Kaspar M; Trachsel E; Menssen HD; Neri D; Garbe C
Clin Cancer Res; 2011 Dec; 17(24):7732-42. PubMed ID: 22028492
[TBL] [Abstract][Full Text] [Related]
6. A new bioassay for the immunocytokine L19-IL2 for simultaneous analysis of both functional moieties.
Winter J; Barbin K; Bacci C; Bunte T
J Pharm Biomed Anal; 2011 Jan; 54(1):81-6. PubMed ID: 20828971
[TBL] [Abstract][Full Text] [Related]
7. Radiotherapy combined with the immunocytokine L19-IL2 provides long-lasting antitumor effects.
Zegers CM; Rekers NH; Quaden DH; Lieuwes NG; Yaromina A; Germeraad WT; Wieten L; Biessen EA; Boon L; Neri D; Troost EG; Dubois LJ; Lambin P
Clin Cancer Res; 2015 Mar; 21(5):1151-60. PubMed ID: 25552483
[TBL] [Abstract][Full Text] [Related]
8. Antibody-based delivery of tumor necrosis factor (L19-TNFα) and interleukin-2 (L19-IL2) to tumor-associated blood vessels has potent immunological and anticancer activity in the syngeneic J558L BALB/c myeloma model.
Menssen HD; Harnack U; Erben U; Neri D; Hirsch B; Dürkop H
J Cancer Res Clin Oncol; 2018 Mar; 144(3):499-507. PubMed ID: 29327244
[TBL] [Abstract][Full Text] [Related]
9. Potentiating the activity of rituximab against mantle cell lymphoma in mice by targeting interleukin-2 to the neovasculature.
Börschel N; Schwöppe C; Zerbst C; Angenendt L; Kessler T; Klapper W; Giovannoni L; Elia G; Neri D; Berdel WE; Mesters RM; Schliemann C
Leuk Res; 2015 Jul; 39(7):739-48. PubMed ID: 25934049
[TBL] [Abstract][Full Text] [Related]
10. Combination of radiotherapy with the immunocytokine L19-IL2: Additive effect in a NK cell dependent tumour model.
Rekers NH; Zegers CM; Yaromina A; Lieuwes NG; Biemans R; Senden-Gijsbers BL; Losen M; Van Limbergen EJ; Germeraad WT; Neri D; Dubois L; Lambin P
Radiother Oncol; 2015 Sep; 116(3):438-42. PubMed ID: 26138057
[TBL] [Abstract][Full Text] [Related]
11. The immunocytokine L19-IL2: An interplay between radiotherapy and long-lasting systemic anti-tumour immune responses.
Rekers NH; Olivo Pimentel V; Yaromina A; Lieuwes NG; Biemans R; Zegers CML; Germeraad WTV; Van Limbergen EJ; Neri D; Dubois LJ; Lambin P
Oncoimmunology; 2018; 7(4):e1414119. PubMed ID: 29632732
[TBL] [Abstract][Full Text] [Related]
12. A novel format for recombinant antibody-interleukin-2 fusion proteins exhibits superior tumor-targeting properties
Ongaro T; Gouyou B; Stringhini M; Corbellari R; Neri D; Villa A
Oncotarget; 2020 Oct; 11(41):3698-3711. PubMed ID: 33110477
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia promotes vasculogenic mimicry formation by inducing epithelial-mesenchymal transition in ovarian carcinoma.
Du J; Sun B; Zhao X; Gu Q; Dong X; Mo J; Sun T; Wang J; Sun R; Liu Y
Gynecol Oncol; 2014 Jun; 133(3):575-83. PubMed ID: 24589413
[TBL] [Abstract][Full Text] [Related]
14. cRGD-functionalized nanoparticles for combination therapy of anti-endothelium dependent vessels and anti-vasculogenic mimicry to inhibit the proliferation of ovarian cancer.
Wang Y; Tong L; Wang J; Luo J; Tang J; Zhong L; Xiao Q; Niu W; Li J; Zhu J; Chen H; Li X; Wang Y
Acta Biomater; 2019 Aug; 94():495-504. PubMed ID: 31252171
[TBL] [Abstract][Full Text] [Related]
15. Ex vivo evaluation of anti-EpCAM immunocytokine huKS-IL2 in ovarian cancer.
Connor JP; Felder M; Hank J; Harter J; Gan J; Gillies SD; Sondel P
J Immunother; 2004; 27(3):211-9. PubMed ID: 15076138
[TBL] [Abstract][Full Text] [Related]
16. Local delivery of IL-2 reduces atherosclerosis via expansion of regulatory T cells.
Dietrich T; Hucko T; Schneemann C; Neumann M; Menrad A; Willuda J; Atrott K; Stibenz D; Fleck E; Graf K; Menssen HD
Atherosclerosis; 2012 Feb; 220(2):329-36. PubMed ID: 22062588
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic efficacy of the F8-IL2 immunocytokine in a metastatic mouse model of lung adenocarcinoma.
Wieckowski S; Hemmerle T; Prince SS; Schlienger BD; Hillinger S; Neri D; Zippelius A
Lung Cancer; 2015 Apr; 88(1):9-15. PubMed ID: 25682318
[TBL] [Abstract][Full Text] [Related]
18. Therapy-induced antitumor vaccination in neuroblastomas by the combined targeting of IL-2 and TNFalpha.
Balza E; Carnemolla B; Mortara L; Castellani P; Soncini D; Accolla RS; Borsi L
Int J Cancer; 2010 Jul; 127(1):101-10. PubMed ID: 19877124
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
